Next, we aimed to mimic the clinical setting by modeling CAR T cell-induced cytokine release syndrome (CRS) in mice, in which CD19 CAR-T cells experience a high tumor burden and initiate CRS within a few days. Here, CD19 is linked to neoplasm.